MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
ABOS — Acumen Pharmaceuticals, Inc. Common Stock
NasdaqAcumen Pharmaceuticals, Inc. Common Stock
$2.07
-0.15(-6.76%)
- O
- 2.22
- H
- 2.29
- L
- 2.07
- V
- 832.15K
⏱️ End-of-day dataAs of Oct 1, 2026
Chart
About ABOS
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateJul 1, 2021
Employees61
Stock ExchangeNasdaq
Ticker SymbolABOS
Websitehttps://www.acumenpharm.com
Key Financial Statistics
| Market Cap | $161.99M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $0.86 - $26.98 |
| 52-Week Avg Volume | 407.7K |
| VWAP | $2.16 |
| Transactions | 5,781 |
| Total Recorded Bars | 1,319 days |